Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Current age and race adjusted prostate specific antigen threshold values delay diagnosis of high grade prostate cancer.

Reed A, Ankerst DP, Pollock BH, Thompson IM, Parekh DJ.

J Urol. 2007 Nov;178(5):1929-32; discussion 1932. Epub 2007 Sep 17.

PMID:
17868724
2.

A framework for the identification of men at increased risk for prostate cancer.

Roobol MJ, Schröder FH, Crawford ED, Freedland SJ, Sartor AO, Fleshner N, Andriole GL.

J Urol. 2009 Nov;182(5):2112-20. doi: 10.1016/j.juro.2009.07.018. Epub 2009 Sep 16. Review.

PMID:
19758625
3.

Population screening for prostate cancer and emerging concepts for young men.

Moul JW.

Clin Prostate Cancer. 2003 Sep;2(2):87-97. Review.

PMID:
15040869
4.

Age specific prostate specific antigen reference ranges: population specific.

Borer JG, Sherman J, Solomon MC, Plawker MW, Macchia RJ.

J Urol. 1998 Feb;159(2):444-8. Review.

PMID:
9649260
5.

Age-specific distribution of serum prostate-specific antigen in a community-based study of African-American men.

Cooney KA, Strawderman MS, Wojno KJ, Doerr KM, Taylor A, Alcser KH, Heeringa SG, Taylor JM, Wei JT, Montie JE, Schottenfeld D.

Urology. 2001 Jan;57(1):91-6. Review.

PMID:
11164150
6.

Racial differences in adenocarcinoma of the prostate in North American men.

Morton RA Jr.

Urology. 1994 Nov;44(5):637-45. Review.

PMID:
7526522
7.

Racial disparity in clinical course and outcome of metastatic androgen-independent prostate cancer.

Thatai LC, Banerjee M, Lai Z, Vaishampayan U.

Urology. 2004 Oct;64(4):738-43. Review.

PMID:
15491712
8.

Race and serum prostate-specific antigen levels: current status and future directions.

Abdalla I, Ray P, Vijayakumar S.

Semin Urol Oncol. 1998 Nov;16(4):207-13. Review.

PMID:
9858327
9.

Populations at high risk for prostate cancer.

Hsieh K, Albertsen PC.

Urol Clin North Am. 2003 Nov;30(4):669-76. Review.

PMID:
14680306
10.

Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer.

Schröder FH, Roobol MJ.

Curr Opin Urol. 2009 May;19(3):227-31. doi: 10.1097/MOU.0b013e328329a2d0. Review.

PMID:
19357513
11.

Prostate cancer in the African American: is this a different disease?

Powell IJ.

Semin Urol Oncol. 1998 Nov;16(4):221-6. Review.

PMID:
9858329
12.

Prostate-specific antigen. Current role in diagnostic pathology of prostate cancer.

Bostwick DG.

Am J Clin Pathol. 1994 Oct;102(4 Suppl 1):S31-7. Review.

PMID:
7524305
13.

Prostate cancer prevention and finasteride.

D'Amico AV, Barry MJ.

J Urol. 2006 Nov;176(5):2010-2; discussion 2012-3. Review.

PMID:
17070238
14.

Epidemiology and pathophysiology of prostate cancer in African-American men.

Powell IJ.

J Urol. 2007 Feb;177(2):444-9. Review.

PMID:
17222606
15.

Prevention of prostate cancer with finasteride: US/European perspective.

Thompson IM, Klein EA, Lippman SM, Coltman CA, Djavan B.

Eur Urol. 2003 Dec;44(6):650-5. Review.

PMID:
14644115
16.

Epidemiology of prostate cancer.

Crawford ED.

Urology. 2003 Dec 22;62(6 Suppl 1):3-12. Review.

PMID:
14706503
17.

Prostate-specific antigen doubling time as a prognostic marker in prostate cancer.

Eastham JA.

Nat Clin Pract Urol. 2005 Oct;2(10):482-91. Review.

PMID:
16474622
18.

[Prostate specific antigen].

Koutani A, Lechevallier E, Coulange C.

Ann Urol (Paris). 1996;30(5):257-61. Review. French.

PMID:
8975592
19.

Defining high-risk prostate cancer: current status.

Fleshner N.

Can J Urol. 2005 Feb;12 Suppl 1:14-7; discussion 94-6. Review.

PMID:
15780159
20.

Is routine digital rectal examination required for the followup of prostate cancer?

Warren KS, McFarlane JP.

J Urol. 2007 Jul;178(1):115-9. Epub 2007 May 11. Review.

PMID:
17499293

Supplemental Content

Support Center